Comparison

Amycretin vs. Exenatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Exenatide

Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Amycretin	Exenatide
Germany	Unapproved	Prescription
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Amycretin and Exenatide?: Amycretin is classified as "Metabolic", while Exenatide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Exenatide?: The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Exenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Exenatide in Germany and the United States?: Germany: Amycretin — Unapproved, Exenatide — Prescription. United States: Amycretin — Unapproved, Exenatide — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Exenatide

Germany

Unapproved

Prescription

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Amycretin and Exenatide?

Amycretin is classified as "Metabolic", while Exenatide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Exenatide?

The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Exenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Exenatide in Germany and the United States?

Germany: Amycretin — Unapproved, Exenatide — Prescription. United States: Amycretin — Unapproved, Exenatide — Prescription. These are factual summaries with source and review date on the individual pages.